Main: +45 31 10 91 91
Fax: +45 77 31 15 09
CVR/VAT no. 31348854
Ordering: +45 29 13 42 24
We are a fast-growing company providing solutions for T cell immune monitoring within immunotherapy, transplantation, infections disease and autoimmunity. Based on our proprietary technology, we develop and market research reagents and diagnostic assays enabling researchers, drug developers, and clinicians to measure disease-specific T cell responses.
The successful candidate will have the opportunity to travel extensively within Western North America for the purpose of maintaining and growing the customer base.
Occasional travel to/from the company headquarters in Copenhagen will be necessary.
Please apply to this position as soon as possible to firstname.lastname@example.org as we will process applications on an ongoing basis. For more information about the position, please contact Stephen Haley, Vice President AMER and Global Strategic Liaison, at (301) 606-9145 or email@example.com.
Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex manufactures MHC Dextramer® for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.
Immudex' MHC Dextramer products are utilized for the quantification or sorting of antigen-specific T cells in life science research, in-vitro diagnostics, as well as the development of immunotherapeutics and vaccines. The primary focus is research-use-only products for the immune monitoring of immunotherapy development and monitoring of CMV cellular immunity in transplant and other immune-deficient patients. In Europe, the CE marked Dextramer CMV Kit is approved for in vitro diagnostic use for the quantification of CMV-specific T cells. USA FDA 510(k) clearance for the CMV kit was granted March 2017. GMP Grade reagents are available.
Our state-of-the-art dCODE Dextramer reagents enable massive multiplexing of antigen-specific T-cell detection. Detection of over 1000 CD8+ T-cell specificities from a single blood sample has been achieved.